5.3 Topoisomerase Inhibitors, Anthracyclines & Cardiotoxicity Mitigation

5.3 Topoisomerase Inhibitors, Anthracyclines & Cardiotoxicity Mitigation

Topoisomerases are ubiquitous nuclear enzymes that resolve DNA topological strain (supercoiling, tangles, catenanes) generated during replication, transcription, and chromatin remodeling. Topoisomerase-targeted antineoplastics act as topoisomerase poisons—they stabilize the transient covalent enzyme-DNA cleavable complex, preventing DNA religation and converting physiological enzymes into cellular DNA-cleaving toxins. When moving replication forks collide with these stabilized complexes, lethal double-strand DNA breaks occur, triggering apoptosis.

---

1. Topoisomerase Classification & Pharmacological Targets

+-----------------------------------------------------------------------------+
|                   TOPOISOMERASE ENZYME TARGETS & AGENTS                     |
|                                                                             |
|   +------------------------------------+--------------------------------+   |
|   |      TOPOISOMERASE I INHIBITORS    |   TOPOISOMERASE II POISONS     |   |
|   +------------------------------------+--------------------------------+   |
|   | - Mechanism: Single-strand break   | - Mechanism: Double-strand break|  |
|   | - ATP-independent                  | - ATP-dependent                |   |
|   | - Agents:                          | - Agents:                      |   |
|   |   * Irinotecan (CPT-11)            |   * Anthracyclines (Doxorubicin|   |
|   |   * Topotecan                      |     Daunorubicin, Epirubicin)  |   |
|   |   * SN-38 (active metabolite)      |   * Anthracenediones           |   |
|   |   * Deruxtecan (ADC payload)       |     (Mitoxantrone)             |   |
|   |                                    |   * Epipodophyllotoxins        |   |
|   |                                    |     (Etoposide, Teniposide)    |   |
|   +------------------------------------+--------------------------------+   |
+-----------------------------------------------------------------------------+

---

2. Anthracyclines: Doxorubicin, Daunorubicin, Epirubicin, Idarubicin

Anthracyclines are among the most active broad-spectrum antineoplastics, utilized in breast cancer, lymphomas, acute leukemias, sarcomas, and pediatric solid tumors.

A. Triple Mechanism of Cytotoxicity:

1. Topoisomerase II$\alpha$ Poisoning: Stabilizes Topo II-DNA cleavable complexes, arresting DNA replication.
2. DNA Intercalation: Planar aglycone ring inserts between adjacent DNA base pairs, blocking transcription and RNA synthesis.
3. Free Radical Generation & Lipid Peroxidation: The quinone moiety undergoes 1-electron reduction via NADPH-cytochrome P450 reductase to semiquinone free radicals. In the presence of molecular oxygen and intracellular iron ($Fe^{2+}/Fe^{3+}$), Fenton reactions generate highly toxic superoxide anions ($O_2^{\bullet-}$) and hydroxyl radicals ($^{\bullet}OH$), inducing membrane lipid peroxidation and DNA strand scission.

+-----------------------------------------------------------------------------+
|               ANTHRACYCLINE CARDIOTOXICITY MECHANISM (TYPE I)               |
|                                                                             |
|   Anthracycline (Doxorubicin) + Intracellular Iron (Fe2+)                   |
|                    |                                                        |
|                    v                                                        |
|   [Redox Cycling of Quinone Ring -> Semiquinone Radical]                    |
|                    |                                                        |
|                    +---> Reacts with O2 -> Superoxide (O2.-)                |
|                    |                                                        |
|                    v                                                        |
|   [Hydroxyl Free Radicals (.OH) & Peroxynitrite Generation]                 |
|                    |                                                        |
|                    v                                                        |
|   [Cardiomyocyte Damage]                                                    |
|   - Cardiomyocytes have low catalase / glutathione peroxidase levels        |
|   - Topoisomerase II-beta inhibition in quiescent myocytes                  |
|   - Mitochondrial DNA degradation & sarcoplasmic reticulum vacuolization    |
|                    |                                                        |
|                    v                                                        |
|   [Myocyte Necrosis / Loss -> Dilated Cardiomyopathy -> Irreversible HF]   |
|                                                                             |
|   *PROTECTION VIA DEXRAZOXANE (ZINECARD):*                                  |
|   Intracellular Iron Chelation + Topo II-beta Catalytic Inhibition          |
|   -> Prevents Free Radical Generation & Protects Myocyte Architecture       |
+-----------------------------------------------------------------------------+

B. Anthracycline-Induced Cardiotoxicity Patterns:

1. Acute / Subacute Cardiotoxicity (Rare, Non-Dose Dependent):
   • Transient ECG changes, sinus tachycardia, ventricular arrhythmias, pericarditis-myocarditis syndrome occurring within 24–48 hours of infusion. Usually self-limiting and clinically reversible.
2. Chronic Cumulative Cardiotoxicity (Type I / Irreversible):
   • Dose-dependent, progressive loss of myofibrils, cytoplasmic vacuolization, and myocyte necrosis leading to dilated cardiomyopathy and congestive heart failure.
   • Lifetime Cumulative Dosing Thresholds:
     • Doxorubicin: $450\text{--}550\text{ mg/m}^2$ (lower threshold of $400\text{--}450\text{ mg/m}^2$ if prior chest/mediastinal radiation, concurrent cyclophosphamide, pre-existing cardiac disease, or concurrent HER2 inhibitors).
     • Daunorubicin: $550\text{--}600\text{ mg/m}^2$
     • Epirubicin: $900\text{ mg/m}^2$
     • Idarubicin: $150\text{ mg/m}^2$
     • Mitoxantrone: $140\text{ mg/m}^2$ (Anthracenedione; causes harmless blue-green discoloration of sclera and urine; high risk of secondary leukemias).

• Cardiac Function Surveillance: Baseline Left Ventricular Ejection Fraction (LVEF) by 2D Echocardiography with strain (or MUGA scan) is mandatory. Re-evaluate periodically as cumulative doses approach safety thresholds or if clinical symptoms develop.

C. Dexrazoxane (Zinecard vs. Totect): Dual Clinical Applications

D. Anthracycline Extravasation Protocol (DNA-Binding Vesicant)

Anthracyclines are potent DNA-binding vesicants. Upon subcutaneous infiltration, the drug binds cellular DNA, causing immediate tissue necrosis; as cells die, the drug is released into adjacent tissues, creating a chronic, deepening ulceration.

• Extravasation Management Algorithm:
  1. Stop infusion immediately; leave catheter in place to aspirate residual drug; do NOT flush line; remove catheter.
  2. Apply DRY COLD COMPRESSES (15–20 minutes 4 times daily for 24–48 hours) to induce vasoconstriction and localize the drug.
  3. Initiate IV Dexrazoxane (Totect) within 6 hours (administered into a separate peripheral vein away from the extravasation site).
  4. Alternative if Totect unavailable: Topical Dimethyl Sulfoxide (DMSO 99%) applied topically ($1\text{--}2\text{ mL}$ every 6–8 hours for 7–14 days).

E. Liposomal Formulations: Pegylated Liposomal Doxorubicin (Doxil)

• Pharmacology: Doxorubicin encapsulated in PEGylated liposomes (stealth liposomes, ~100 nm). Evades reticuloendothelial clearance, yielding a prolonged circulation half-life (~55 hours vs. 5 minutes for conventional doxorubicin).
• Toxicity Profile Shift: Stealth liposomes cannot penetrate the tight junctions of myocardial capillaries $\rightarrow$ drastically reduced cardiotoxicity. However, liposomes extravasate into cutaneous capillaries under pressure/friction $\rightarrow$ high incidence of Hand-Foot Syndrome (PPE) and severe infusion-related reactions (pseudo-allergic complement activation; infuse slowly at $1\text{ mg/min}$). NOT interchangeable with conventional doxorubicin on a mg-per-mg basis!

---

3. Topoisomerase I Inhibitors: Irinotecan & Topotecan

+-----------------------------------------------------------------------------+
|               IRINOTECAN (CPT-11) METABOLISM & DIARRHEA MANAGEMENT          |
|                                                                             |
|            IRINOTECAN (Prodrug)                                             |
|                 |                                                           |
|                 | (Hepatic Carboxylesterases - CES1/CES2)                   |
|                 v                                                           |
|            SN-38 (Active Topo I Inhibitor, 1000x Potency)                   |
|                 |                                                           |
|                 | (Hepatic Glucuronidation via UGT1A1)                      |
|                 v                                                           |
|            SN-38G (Inactive Glucuronide Conjugate)                          |
|                 |                                                           |
|                 +---> Biliary Excretion into Intestinal Lumen               |
|                       |                                                     |
|                       v                                                     |
|            [Bacterial Beta-Glucuronidase in Gut]                            |
|            (Deconjugates SN-38G back to active SN-38)                       |
|                       |                                                     |
|                       v                                                     |
|            DIRECT ENTEROCYTE MUCOSAL DAMAGE & HYPERSECRETION                |
|                       |                                                     |
|                       v                                                     |
|            DELAYED DIARRHEA (>24 Hours Post-Infusion)                       |
|            - Treatment: HIGH-DOSE LOPERAMIDE REGIMEN                        |
|            - 4 mg at onset, then 2 mg q2h until diarrhea-free for 12 hours  |
|            - If refractory >48h: OCTREOTIDE 100-500 mcg SC TID              |
+-----------------------------------------------------------------------------+

A. Acute vs. Delayed Diarrhea Syndromes:

1. Early / Acute Diarrhea & Cholinergic Syndrome ($<24\text{ hours}$):
   • Mechanism: Direct inhibition of acetylcholinesterase by the parent irinotecan molecule, causing acute cholinergic hyperstimulation.
   • Symptoms: Abdominal cramping, acute watery diarrhea, diaphoresis, lacrimation, salivation, miosis, and bradycardia occurring during or within hours of infusion.
   • Treatment & Prophylaxis: Atropine $0.25\text{ to }1.0\text{ mg IV or SC}$. Administer therapeutically or as pre-medication for subsequent cycles.
2. Late / Delayed Diarrhea ($>24\text{ hours}$ post-infusion):
   • Mechanism: Direct cytotoxic mucosal injury and hypersecretion mediated by SN-38 in the bowel lumen following bacterial $\beta$-glucuronidase reactivation.
   • Management Protocol:
     • High-Dose Loperamide Protocol: Initiate at the first loose stool: 4 mg PO initially, then 2 mg PO every 2 hours (or 4 mg every 4 hours during sleep) until diarrhea-free for 12 consecutive hours. (This exceeds standard OTC 16 mg/day maximums under supervised oncology guidance).
     • Refractory Diarrhea ($>48\text{ hours}$ on loperamide): Escalate to Octreotide ($100\text{--}500;\mu\text{g SC TID}$) and initiate oral fluoroquinolone prophylaxis (e.g., Ciprofloxacin) to prevent bacteremia/sepsis from intestinal transmigration.

B. UGT1A1 Pharmacogenomics:

• $UGT1A1*28$ Variant: Characterized by 7 TA repeats in the promoter region ($[TA]_7TAA$) compared to 6 repeats in wild-type ($*1$). Homozygosity ($*28/*28$, present in ~10% of Caucasians) reduces hepatic glucuronidation of SN-38 by $>70%$.
• Clinical Consequence: Severe, life-threatening Grade 4 neutropenia and debilitating delayed diarrhea. Consider upfront dose reductions of irinotecan ($25\text{--}30%$) in patients known to be homozygous for $UGT1A1*28$.

---

4. Epipodophyllotoxins: Etoposide (VP-16) & Teniposide

• Mechanism: Forms a ternary complex with Topoisomerase II and DNA, preventing religation of double-strand breaks during late S and G2 phases.
• Formulation & Infusion Parameters:
  • IV etoposide is formulated with polysorbate 80, polyethylene glycol, and benzyl alcohol. Rapid IV infusion causes severe hypotension and bronchospasm. Must be infused over at least 30 to 60 minutes.
  • Non-PVC Bags & Tubing: Etoposide at concentrations $>0.4\text{ mg/mL}$ can precipitate and leach diethylhexyl phthalate (DEHP) from standard PVC bags. Use polyolefin/glass containers and non-PVC tubing.
• Oral Etoposide Bioavailability: Oral bioavailability is approximately $50%$ (ranging 30–75%). When converting from IV to oral etoposide, the oral dose is calculated as double the IV dose (Oral Dose = $2\times\text{IV Dose}$), rounded to the nearest 50 mg capsule size.
• Secondary Malignancy (t-AML / Therapy-Related Leukemia):
  • Topoisomerase II inhibitors (etoposide, anthracyclines) carry a distinct risk of therapy-related acute myeloid leukemia (t-AML).
  • Molecular Hallmark: Balanced chromosomal translocations involving the $MLL$ / $KMT2A$ gene at chromosome 11q23 (or $PML-RARA$ at $t(15;17)$).
  • Clinical Characteristic: Short latency period (1 to 3 years post-exposure), without an antecedent myelodysplastic syndrome (MDS) phase, presenting acutely with monocytic (FAB M4/M5) features.